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ABSTRACT
Purpose: To determine the maximum-tolerated dose,
toxicity profile, and pharmacokinetics of a fixed dose of
paclitaxel followed by increasing doses of carboplatin, given
weekly to patients with advanced esophageal or gastric junc-
tion cancer.
Experimental Design: Paclitaxel was administered on
day 1 as a 1-h infusion at a fixed dose of 100 mg/m2 followed
by a 1-h infusion of carboplatin targeting an area under the
curve (AUC) of 2–5 mg  min/ml, with cycles repeated on
days 8, 15, 29, 36, and 43.
Results: Forty patients [36 males; median (range) age,
57 (40–74) years] were enrolled. Dose-limiting toxicity was
observed at a carboplatin AUC of 5 mg  min/ml and
consisted of treatment delay attributable to myelosuppres-
sion. No grade 3/4 treatment-related nonhematological tox-
icity was observed. The highest dose intensity (>95% of the
planned dose over time) was achieved with a carboplatin
AUC of 4 mgmin/ml. The mean (SD) AUCs of unbound
(Cu) and total paclitaxel were 0.662 0.186 and 7.37 1.33
M  h, respectively. Clearance of Cu was 188  44.6
liter/h/m2, which is not significantly different from historical
data (P  0.52). Cremophor EL clearance was 123  23
ml/h/m2, similar to previous findings. Of 37 patients evalu-
able for response, 1 had complete response, 19 had partial
response, and 10 had stable disease, accounting for an over-
all response rate of 54%.
Conclusions: This regimen is very tolerable and effec-
tive, and the recommended doses for additional studies are
paclitaxel (100 mg/m2), with carboplatin targeting an AUC
of 4 mg  min/ml.
INTRODUCTION
Esophageal cancer is among the 10 most frequently occur-
ring human malignancies in the world. Although the incidence
of squamous cell cancer remains relatively constant, the inci-
dence of adenocarcinoma of the distal esophagus or esophageal–
gastric junction is rapidly increasing in Western countries, in-
cluding the United States (1). This rising incidence is not
completely explained yet, but obesity, gastric reflux, and the
development of an intestinalized columnar epithelium (Barrett’s
esophagus) in the squamous lining of the esophagus have been
identified as important risk factors for development of adeno-
carcinomas in the distal esophagus (2–4). Approximately 50%
of the patients present with systemic disease and the majority of
patients being treated for localized disease will develop meta-
static disease with or without local recurrence after esophageal
resection.
Cisplatin-based chemotherapy regimens are commonly
used as preoperative treatment for patients with resectable dis-
ease or patients with advanced disease. In combination with
5-fluorouracil, response rates of 35% in metastatic and 45–55%
in locoregional disease have been reported (5). More recently,
irinotecan and paclitaxel have been identified as new agents in
the treatment of esophageal cancer. The response rate after
treatment with irinotecan, administered weekly as a single
agent, was 15% (6), and in combination with cisplatin, the
response rate was 57% (7). Combination therapy of cisplatin and
paclitaxel, either administered weekly, biweekly or every 3
weeks, in patients with advanced esophageal cancer has been
evaluated previously, with response rates ranging from 42 to
52% (8–12). When paclitaxel was administered over 24 h in
combination with cisplatin with or without 5-fluorouracil, the
predominant toxicity was myelosuppression (8, 9). Myelotoxic-
ity was less severe when paclitaxel was administered over 3 h in
a weekly or biweekly schedule in combination with cisplatin,
although the incidence and severity of sensory neurotoxicity
increased (10–12).
Recently, the safety and efficacy of weekly administrations
of paclitaxel in patients with breast, ovarian, and lung cancer
have been reported (13–16). Doses of 100–175 mg/m2/week are
well tolerated with minimal hematological toxicity and revers-
ible neurotoxicity (14). Furthermore, it is possible to combine
weekly paclitaxel administration with carboplatin either in a
weekly schedule at a dose to produce a target area under the
plasma concentration time curve (AUC) of 2 mg/ml  min
(AUC 2) or every 3 weeks at dose level targeting AUC 6 (17).
On the basis of our favorable experience with dose-dense bi-
weekly and weekly schedules of cisplatin and paclitaxel, we
initiated a dose-finding study with a weekly schedule of a fixed
dose of paclitaxel and escalating doses of carboplatin. The
advantage of a paclitaxel–carboplatin regimen over a cisplatin–
paclitaxel regimen is that it can be given as an outpatient
treatment and probably induces less neurotoxicity. The objec-
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tives of this study were to assess the safety and toxicity of this
combination and determine the dose-limiting toxicities (DLT),
maximum-tolerated dose (MTD), and recommended dose for
further evaluation.
PATIENTS AND METHODS
Eligibility. Patients with histological proven metastatic
or unresectable adenocarcinoma, undifferentiated or squamous
cell carcinoma of the esophagus or gastro-esophageal junction
area were eligible for the study. Tumors invading adjacent
structures (T4) or with proven distant metastases (M1a or M1b)
were considered unresectable. Additional eligibility require-
ments included: (a) life expectancy of 12 weeks; (b) age 18
years; (c) WHO performance status 0–2; adequate hematolog-
ical (granulocytes  1.5  109/liter and platelets  100 
109/liter); (d) renal (serum creatinine  120 mol/liter); and (e)
hepatic functions (total bilirubin  1.5  upper normal limit).
Patients with neurotoxicity graded1 according to the National
Cancer Institute Common Toxicity Criteria (CTC) version 2
were not eligible. Previous radiation for primary or metastatic
disease was allowed but not in the 4 weeks before study entry
and when not involving 30% of the bone marrow. Patients
treated previously with chemotherapy were not eligible. The
study was approved by the Erasmus Medical Center ethics
committee (Rotterdam, the Netherlands), and all patients pro-
vided written informed consent.
Pretreatment and Follow-Up. Before treatment, a com-
plete medical history was taken, and physical examination,
laboratory studies, electrocardiogram, and imaging studies for
tumor measurements were performed. Laboratory studies in-
cluded a complete blood cell count analysis with WBC differ-
ential, sodium, potassium, calcium, phosphorus, urea, creati-
nine, total protein, albumin, bilirubin, alkaline phosphatase,
alanine aminotransferase, aspartate aminotransferase, and lac-
tate dehydrogenase.
History, physical examination, and toxicity scoring accord-
ing to National Cancer Institute CTC definitions were per-
formed weekly. Blood cell counts and serum chemistry studies
were also performed weekly. Tumor measurements were per-
formed after six administrations by a computed tomography
scan of the chest and upper abdomen. Patients with the primary
tumor in situ were also evaluated by endoscopy. Standard WHO
response criteria were used (18). Duration of response was
calculated difinitions from the start of treatment.
Drug Administration. All patients received dexametha-
sone (10 mg), clemastine (2 mg), and ranitidine (50 mg), ad-
ministered i.v. 30 min before paclitaxel infusion. Patients re-
ceived paclitaxel as a 1-h infusion diluted in 500 ml of sterile
and isotonic (0.9%, volume for volume) sodium chloride solu-
tion (saline), with the total drug dose normalized to a patient’s
body surface area. After the completion of the paclitaxel infu-
sion, 100 ml of saline were infused over 30 min, followed by an
infusion of ondansetron (8 mg) diluted in 100 ml of saline given
over 30 min. Hereafter, the total calculated dose of carboplatin,
diluted in 500 ml of 5% (weight/volume) dextrose solution, was
administered in 1 h.
Study Design. Paclitaxel and carboplatin were adminis-
tered on days 1, 8, 15, 29, 36, and 43. The paclitaxel dose was
fixed at 100 mg/m2/administration, and the starting dose of
carboplatin was set at a targeted AUC of 2 according to a
formula published previously (19). The creatinine clearance was
estimated by the Cockcroft-Gault equation. The carboplatin
dose was escalated per cohort in steps targeting an increase in
AUC of 0.5 mg/ml  min. In each cohort, 3 patients were
treated until DLT was observed. If two or more DLTs were
observed, that dose was considered too high. In the case of one
DLT, the accrual of 3 additional patients was required. If DLT
was seen in no more than 1 patient at that dose level, the dose
was to be further escalated. The dose level at which 2 patients
experienced DLT was considered the MTD. The dose below
MTD would be the recommended dose for additional studies.
DLT was defined as any of the following events occurring
during treatment: (a) grade 3–4 neutropenia with infection or
fever requiring parenteral antibiotics; (b) grade 3–4 thrombo-
cytopenia requiring two or more platelet transfusions or result-
ing in more than or equal to grade 2 hemorrhage; (c) nonhema-
tological toxicity more than or equal to grade 3 with the
exception of acute nausea and/or vomiting; and (d) and/or dose
reductions and/or treatment delay for 1 week for reasons of
toxicity.
Patients were retreated on days 8 and 15 provided the WBC
was1  109/liter and platelets were50  109/liter, whereas
before the start of the day 29 course, the WBCs had to be 3 
109/liter and platelets  100  109/liter. When these criteria
were not met, treatment was postponed for 1 week. If bone
marrow recovery was still insufficient after this week, patients
were taken off study. Dose reduction was performed in patients
with neutropenic fever or grade 3–4 thrombocytopenia requir-
ing two or more platelet transfusions or resulting in more than or
equal to grade 2 hemorrhage; in that case, patients were re-
treated at the preceding dose level. Responding patients could
receive additional local therapy in case of limited lymph node
metastasis or additional cycles of carboplatin and paxlitaxel in
case of distant metastatic disease. These additional cycles could
also be administered in a traditional 3-weekly schedule.
After establishing a recommended dose, 8 additional pa-
tients would be treated at this dose level. This was done to
demonstrate the feasibility and to estimate the dose-intensity of
this schedule. Pharmacokinetic analysis were performed in these
patients.
Sampling Schedule and Drug Analysis. Blood volumes
of 5 ml were drawn directly into Vacutainer tubes containing
lithium heparin (Becton Dickinson, Meylin, France) from a
peripheral venous access device. Samples were collected at the
following time points: (a) immediately before paclitaxel treat-
ment; (b) at 0.5 h after the start of infusion; (c) 5 min before the
end of infusion; and (d) at 0.5, 1, 3, 7, and 23 h after the end of
infusion. After centrifugation at 2000  g for 5 min, the plasma
fraction was separated, transferred into a clean polypropylene
tube, and stored frozen at 20°C until analysis. Total concen-
trations of paclitaxel (i.e., the total of bound and unbound) in
plasma were determined by a validated reversed phase high-
performance liquid chromatographic assay with detection at a
wavelength of 230 nm, as described previously (20). This assay
has a lower limit of quantitation of 10 ng/ml, with an accuracy
(i.e., percentage deviation from nominal concentrations) of
3%. Unbound concentrations of paclitaxel in plasma were
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obtained from an equilibrium dialysis method using generally
tritium-labeled paclitaxel as a tracer (21). The analytical proce-
dure for Cremophor EL was based on a colorimetric dye-
binding microassay using Coomassie-Brilliant Blue G-250 (Bio-
Rad Laboratories, Munchen, Germany), according to a
published procedure (22). The lower limit of quantitation of this
procedure was 0.5 l/ml, with an accuracy of 6.5%.
Pharmacokinetic Data Analysis. The fractions unbound
(fu) paclitaxel in each individual patient plasma sample, includ-
ing the blank, were determined after analysis for total radioac-
tivity (i.e., [3H]paclitaxel) by liquid scintillation counting. The
unbound drug concentrations (Cu) were calculated from the
fraction unbound drug (fu) and total drug concentration (Cp; i.e.,
the total of unbound, protein bound and Cremophor EL associ-
ated), as Cu  fu  Cp. Estimates of pharmacokinetic param-
eters for unbound paclitaxel and total paclitaxel in plasma were
derived from individual concentration time data sets by a linear
multicompartmental analysis using the software package Siphar
version 4.0 (InnaPhase, Philadelphia, PA). This program deter-
mines the slopes and intercepts of the logarithmically plotted
curves of multiexponential functions using nonlinear least
squares, iterative steps. Initial parameter estimates were deter-
mined by an automated curve-stripping procedure. The mathe-
matical equations describing the drug concentration C(t) at any
time t during and after i.v. administration are given by C(t)  
[Ci/(	i  Tinf) (1 e(	i  t))] and C(t)   [Ci/(	i  Tinf)
(e(	i  [t  Tinf])  e(	i  t))], respectively. In these equations,
	i is the component of the i-th exponential term, Ci is the initial
concentration of the i-th component of the curve, and Tinf is the
infusion duration. In all cases, paclitaxel concentration time
curves were best described with a tri-exponential model, which
gave the lowest Akaike information criterion, without any dem-
onstration of saturable behavior (R2 0.996 0.002, root mean
square error  14  3.5%). The curve fitting procedure with
this model yields the parameters C1, C2, C3, 	1, 	2, and 	3. The
AUC values were determined on the basis of the parameters of
the equations with extrapolation to infinity using the terminal
disposition rate constant. The clearance was defined as dose
(expressed in mol/m2) divided by AUC. The volume of dis-
tribution at steady state was calculated as the product of clear-
ance and the mean residence time, also estimated from the
equations. Peak plasma concentrations were put on par with
observed (experimental) drug levels immediately after the end
of infusion.
Estimates of pharmacokinetic parameters for Cremophor
EL in plasma were derived from individual concentration time
data sets by noncompartmental analysis using the software
package WinNonLin version 3.0 (Pharsight Corp., Mountain
View, CA). The peak plasma concentrations and time to peak
were the observed values. The AUC was calculated using the
log-linear trapezoidal method from time 0 to the time of the final
quantifiable concentration [AUC(tf)]. The AUC was also ex-
trapolated to infinity by dividing the last measured concentra-
tion by the rate constant of the terminal phase (k), determined by
linear regression analysis of the last three measurable concen-
trations (R2  0.983  0.021). The systemic clearance was
calculated by dividing the administered dose (expressed in mi-
croliters) by the observed AUC(inf), and the terminal disposi-
tion half-life was calculated as ln (2)/k.
All pharmacological parameters are expressed as mean
values  SD, unless stated otherwise. Interindividual variability
in parameters was expressed as the coefficient of variation,
calculated as the ratio of the SD and observed mean, and
multiplied by 100. The effect on the two different targeted
carboplatin exposure levels (AUC of 4 and 4.5) on the generated
data was evaluated statistically using a nonparametric Wilcoxon
(two group) test. A comparative analysis with data obtained
from patients receiving single-agent paclitaxel with those ob-
tained in the current trial was performed using a nonparametric
Kruskal-Wallis (multiple group) test. The level of significance
was set at P  0.05. All statistical calculations were performed
using JMP version 3.2.6 (SAS Institute, Inc., Cary, NC).
Pharmacodynamic analysis was not performed, because the
number of patients that were analyzed was too small.
RESULTS
Patients and Toxicity Profiles. A total of 40 eligible
patients entered the study. Patient characteristics are shown in
Table 1. Two patients had pulmonary embolism 2 weeks after
start of treatment; both patients recovered and were able to
complete treatment. As these patients had a treatment delay
attributable to other reasons than chemotherapy-induced toxic-
ity, they were considered not to be fully assessable for toxicity.




















Squamous cell carcinoma 5 13
Undifferentiated carcinoma 1 3
Location primary tumor
Proximal esophagus 1 3
Mid 7 18
Distal 19 48
Gastroesophageal junction 13 33
Extent of disease
Locally advanced/unresectable 0
Primary with distant metastases 30 75
Metastases after primary resection 10 25
Metastatic sites
Lymph nodes only 7 18
Liver 18 45
Other 15 38
a ECOG, Eastern Cooperative Oncology Group.
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One patient refused further treatment after two courses of chem-
otherapy.
The carboplatin dose was increased from the first dose
level (AUC 2) to dose level AUC 5. At dose level AUC 4, 1
patient had DLT after three administrations, consisting of neu-
tropenic fever and grade 3 diarrhea. She had to be admitted and
recovered after treatment with i.v. broad spectrum antibiotics.
At the dose level AUC 4.5, another patient had a DLT. This
patient developed neutropenic fever after the third course of
treatment and also recovered after antibiotic treatment. Both
patients treated at carboplatin dose level AUC 5 had a treatment
delay-related DLT. These 2 patients were not able to continue
treatment at day 29, and treatment had to be delayed for 2 and
3 weeks, respectively, because of protracted myelosuppression;
consequently, this dose level was considered to be the MTD. As
per protocol, 8 patients were additionally treated at carboplatin
level AUC 4.5, and pharmacokinetic analyses were performed.
However, treatment delay frequently occurred at this dose level,
and therefore, 6 additional patients were treated at carboplatin
dose AUC 4. Pharmacokinetic analyses were also performed at
this latter dose level.
Toxicity data are shown in Tables 2 and 3. Neutropenia
grade 3 or 4 was observed in 25 (77%) patients. The granulocyte
nadir usually occurred after the fifth or sixth treatment course.
Thrombocytopenia grade 3 or 4 was observed in 4 patients and
occurred at carboplatin dose levels of AUC  4. Nonhemato-
logical toxicity predominantly consisted of sensory neurotoxic-
ity grade 1 or 2 occurring in 7 (19%) and 2 (5%) patients,
respectively. Fatigue was observed in 24 (65%) patients and did
not appear to be dose related. Nephrotoxicity did not occur.
Alopecia was universal.
A total of 215 administrations was given. Table 4 shows
the achieved dose intensity and observed treatment delays. Thir-
teen (6%) administrations were delayed in 11 (30%) patients,
and almost all delays occurred at day 29. Five administrations
had to be delayed because of unresolved thrombocytopenia, one
administration because of leucocytopenia, and five administra-
tions because of both thrombocytopenia and leucocytopenia.
One patient had two administrations delayed for 1 week because
of fatigue. A treatment delay caused by myelotoxicity also was
observed in 8 of 11 patients treated at carboplatin dose level
AUC 4.5. Therefore, we considered carboplatin targeted at AUC
4 the recommended dose for weekly treatment in combination
with paclitaxel administered at 100 mg/m2. Because at this dose
level only 1 patient had a treatment delay of 1 week, we
achieved the highest dose intensity for paclitaxel and carbopla-
tin. The median dose intensity at dose level AUC 4 after six
courses calculated over an 8-week period was 75 mg/m2/week
for paclitaxel and AUC 3/week for carboplatin.
Drug Disposition. Pharmacokinetic analysis of unbound
and total paclitaxel was performed during the first cycles of
treatment in 14 patients treated at a carboplatin AUC of 4 or 4.5
(Table 5). A summary of the plasma pharmacokinetic parame-
ters is presented in Table 6. Moderate interindividual variability
in paclitaxel AUC was noted, both for the unbound fraction (i.e.,

28%) as well as for total drug (i.e., 
18%). The exposure to
unbound paclitaxel was not significantly different in patients
receiving either carboplatin targeted at an AUC of 4 or 4.5, with






0 1 2 3 4 0 1 2 3 4 0 1 2 3 4
AUC 2b 3/18 1 0 1 1 0 3 0 0 0 0 2 1 0 0 0
AUC 2.5 3/18 0 1 1 1 0 2 1 0 0 0 0 3 0 0 0
AUC 3 3/18 0 0 2 1 0 2 1 0 0 0 1 2 0 0 0
AUC 3.5 3/18 0 0 0 2 1 2 1 0 0 0 1 2 0 0 0
AUC 4 12/68 0 0 1 4 7 5 5 1 0 1 3 6 3 0 0
AUC 4.5 11/63 0 1 2 5 3 3 4 3 1 0 4 3 4 0 0
AUC 5 2/12 0 0 0 1 1 0 0 0 2 0 1 1 0 0 0
a Graded according to National Cancer Institute common toxicity criteria.
b AUC, area under the plasma concentration time curve (in mg  min/ml).





Nauseaa Vomitinga Neurotoxicitya Diarrheaa Fatiguea
0 1 2 3 4 0 1 2 3 4 0 1 2 3 4 0 1 2 3 4 0 1 2 3 4
AUC 2b 3/18 2 0 1 0 0 2 0 1 0 0 3 0 0 0 0 2 0 1 0 0 0 1 2 0 0
AUC 2.5 3/18 0 3 0 0 0 2 1 0 0 0 2 1 0 0 0 3 0 0 0 0 0 2 1 0 0
AUC 3 3/18 1 2 0 0 0 3 0 0 0 0 3 0 0 0 0 2 1 0 0 0 1 1 1 0 0
AUC 3.5 3/18 1 2 0 0 0 3 0 0 0 0 2 1 0 0 0 2 1 0 0 0 1 2 0 0 0
AUC 4 12/68 5 5 2 0 0 9 3 0 0 0 8 3 1 0 0 5 4 2 1 0 4 4 4 0 0
AUC 4.5 11/63 3 4 4 0 0 8 3 0 0 0 8 2 1 0 0 9 1 1 0 0 4 6 0 1 0
AUC 5 2/12 1 1 0 0 0 2 0 0 0 0 1 1 0 0 0 1 1 0 0 0 1 1 0 0 0
a Graded according to National Cancer Institute common toxicity criteria.
b AUC, area under the plasma concentration time curve (mg  min/ml).
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mean values of 0.611  0.108 versus 0.69  0.219 M  h,
respectively [mean difference (SE), 0.078  0.105; 95%
confidence limits, 0.151 and 0.308; P  0.47]. Likewise, the
AUC of total paclitaxel was similar in both groups, with mean
values of 7.6  1.47 versus 6.96  1.04 M  h, respectively
[mean difference (SE), 0.63  0.75; 95% confidence limits,
1 and 2.26; P  0.42]. The absolute clearance of unbound
paclitaxel was also not significantly different from historical
data obtained in 15 patients treated with single-agent paclitaxel
as a 1-h infusion at 100 mg/m2 (P  0.52; Ref. 23).
Cremophor EL concentrations in plasma from 1 patient
remained undetectable beyond 8 h after the end of infusion; this
was not the result of technical errors but of interindividual
pharmacokinetics of Cremophor EL. Pharmacokinetic parame-
ters for this patient are not listed in Table 7. Disappearance of
Cremophor EL from the plasma compartment was characterized
by elimination in an apparent biexponential manner, with a
mean overall clearance of 123  23 ml/h/m2. The AUC of
Cremophor EL was similar to that reported in patients treated
with paclitaxel in the absence of carboplatin coadministration
[70.5  16.4 (range, 54.6–107) versus 80.2  24.2 (range,
46.3–123) l  h/ml; P  0.21; Ref. 23].
Response and Survival. Thirty-seven patients were
evaluable for response. All these patients had bidimensionally
measurable disease. One patient with a tumor in the proximal
esophagus and supraclavicular lymph node metastasis achieved
a complete response. This patient received additional radiation
therapy to a total dose of 50 gray, and he is alive without
evidence of disease after a follow-up of 19 months. A partial
response was observed in 19 patients (51%). The median dura-
tion of partial and complete responses was 9 months (range,
5–30 months). Ten patients had stable disease, and 7 patients
had progressive disease. The overall response rate was 54%.
Two responding patients with adenocarcinomas of the distal
esophagus and celiac lymph node metastases underwent an
esophageal resection after chemotherapy. Both patients had
radical resections and are currently alive without evidence of
disease after a follow-up of 18 and 16 months, respectively.
Eleven patients with a partial response after chemotherapy and
4 patients with stable disease received additional treatment with
chemotherapy. The median survival for all 40 patients was
11 months (range, 3–30 months), with a 1-year survival rate
of 46%.






with a delay (%)
No. of administrations





AUC 2 3/18 0 0 0 1.5
AUC 2.5 3/18 0 0 0 1.9
AUC 3 3/18 0 0 0 2.3
AUC 3.5 3/18 1 1 2 2.4
AUC 4 12/68 1 (8%) 1 (1%) 1 3.0
AUC 4.5 11/63 7 (64%) 8 (13%) 11 2.9
AUC 5 2/12 2 (100%) 3 (25%) 6 2.7
a AUC, area under the plasma concentration time curve (in mg  min/ml).
b Dose intensity calculated over 8 weeks.
Table 5 Demographics of patients sampled for pharmacologic
analysis (n  14)a
Median Range
Baseline screening
Age, years 56 42–66
BSA, m2b 1.95 1.78–2.18
Height, cm 177 169–187
Weight, kg 80 65–99
Pretherapy hematology
Hematocrit, liter/liter 0.40 0.36–0.46
Leukocytes,  109/liter 9.0 5.0–15
Neutrophils,  109/liter 6.2 3.2–13
Pretherapy clinical chemistry
AST, units/liter 25 12–38
ALT, units/liter 24 12–38
ALP, units/liter 105 72–160
GGT, units/liter 70 19–208
Total serum bilirubin, mol/liter 8 4–14
Serum creatinine, mol/liter 71 52–82
a n, total number of patients studied.
b BSA, body surface area; AST, aspartate amino-transferase; ALT,
alanine aminotransferase; ALP, alkaline phosphatase; GGT, -glutamyl-
transferase.
Table 6 Summary of paclitaxel pharmacokinetic parameters
(n  14)a,b
Parameter Mean  SD Range
Paclitaxel dose, mg 195  12.7 178–216
Infusion duration, h 1.05  0.10 1.00–1.38
Unbound paclitaxel
Cmax, Mc 0.349  0.121 0.231–0.696
AUC, M  h 0.662  0.186 0.425–1.18
CL, liter/h/m2 188  44.6 99.6–276
Vss, liter/m2 1250  661 649–3210
T1/2,z, h 9.69  4.91 5.55–25.7
AUC/AUC, % 8.9  1.1 7.6–12
Total paclitaxel
Cmax, M 3.98  1.07 2.95–7.04
AUC, M  h 7.37  1.33 5.60–10.2
T1/2,z, h 8.84  1.79 7.09–13.53
a All patients received paclitaxel as a 1-h infusion at a dose of 100
mg/m2 followed by carboplatin at a dose targeting an AUC of 4 mg 
min/ml (n  5) or AUC of 4.5 mg  min/ml (n  9). Data were
calculated using a three-compartment model.
b n, total number of patients studied.
c Cmax, peak plasma concentration; AUC, area under the plasma
concentration time curve; CL, plasma clearance; Vss, volume of distri-
bution at steady state; T1/2,z, half-life of the terminal disposition phase;
AUC/AUC, ratio of unbound to total drug on the basis of AUC.
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DISCUSSION
Chemotherapy with or without radiotherapy is frequently
used in the treatment of patients with resectable esophageal
cancer. Although the outcome of trials reported previously is
contradictory, a recently reported large study on preoperative
chemotherapy demonstrated a significant survival benefit (24).
The role of chemotherapy as palliative treatment for patients
with recurrent or metastatic disease has been less well estab-
lished. In one randomized study, patients with advanced disease
were randomized between treatment with cisplatin and 5-flu-
orouracil or cisplatin alone (25). The higher response rate in the
cisplatin/5-fluorouracil arm (37 versus 18%) did not translate in
an improved survival, most likely because 16% treatment-re-
lated deaths were observed in the cisplatin/5-fluorouracil arm
compared with 0% in the cisplatin arm. In other randomized
studies, patients with esophageal and gastric cancer are both
included, so it is difficult to draw conclusions (26, 27).
In this Phase I study, we treated patients with metastatic
esophageal cancer with paclitaxel 100 mg/m2 in combination with
escalating doses of carboplatin administered on days 1, 8, 15, 29,
36, and 43. At carboplatin dose level AUC 5, the MTD was reached
and consisted of a treatment delay of 2 weeks on day 29. The
highest dose intensity was achieved at carboplatin dose level AUC
4, and therefore, we recommend this dose level for additional
studies. In general, this weekly schedule of carboplatin and pacli-
taxel was both well tolerated and convenient to administer in the
outpatient setting. Although neutropenia grade 3 or 4 occurred in
77% of the patients, only 2 patients (5%) developed neutropenic
fever. Therefore, we consider the myelotoxicity to be acceptable.
Other toxicities were either absent or mild.
Sehouli et al. (28) recently reported on a Phase I study in
which patients with ovarian cancer untreated previously were
treated with a weekly combination of 100 mg/m2 paclitaxel (1-h
infusion) and escalating doses of carboplatin. Patients were
treated for six consecutive weeks, followed by a 2-week break
and another 6 weekly courses. Myelotoxicity was dose limiting
at carboplatin dose levels  AUC 2. The difference in MTD
between this and our study might be explained by the fact that
we treated our patients for three consecutive weeks followed by
a 1-week break. After a 1-week break, myelotoxicity recovered
in almost all patients treated at the recommended dose level. In
addition, we administered only 6 weekly cycles, and the MTD
for carboplatin could be lower for 12 cycles because of cumu-
lative myelotoxicity or neurotoxicity.
The achieved dose intensity calculated over 8 weeks at the
recommended dose level of carboplatin AUC 3/week and pacli-
taxel 75 mg/m2/week is high in comparison with other schedules
of carboplatin administered either as a single agent or in com-
bination with paclitaxel. In patients with ovarian cancer un-
treated previously, the MTD for four cycles of carboplatin as
single agent was AUC 12 when carboplatin was administered
every 4 weeks (29) and AUC 7 when carboplatin was adminis-
tered every 2 weeks with the use of granulocyte colony-stimu-
lating factor (30), however, at the cost of severe thrombocyto-
penia. In combination with 225 mg/m2 paclitaxel, the MTD for
carboplatin was AUC 8 in a 3-weekly schedule, however, also at
the cost of considerable toxicity.
In previous clinical trials, it has been demonstrated that con-
current carboplatin does not change the disposition of paclitaxel
after 3-h infusions (31, 32). Likewise, a number of reports docu-
mented unaltered pharmacokinetics of carboplatin attributable to
pretreatment with paclitaxel at standard doses used in 3-weekly
regimens (33, 34). Our current study adds to that knowledge by
demonstrating that carboplatin also does not modulate paclitaxel
disposition after shorter infusions. We also tested the hypothesis
that carboplatin might alter the extent of paclitaxel protein binding
but found no effect on the fraction unbound paclitaxel relative to
historical control data (23). In line with several independent studies
(reviewed in Ref. 35), we noted that therapy-associated thrombo-
cytopenia was less than expected in patients treated with the com-
bination of paclitaxel and carboplatin. In the absence of a pharma-
cokinetic interaction, the reason for this phenomenon is still
unclear, although several possible explanations have been invoked.
Experimental studies have shown an antagonistic interaction be-
tween the two drugs in the megakaryoblast cell line MEG-01 as a
model of a platelet precursor (36), which may involve induced
production of hematopoietic cytokines, including thrombopoietin,
possibly combined with gluthatione S-transferase-mediated detox-
ification of carboplatin (37). Alternatively, we have recently shown
that Cremophor EL, at concentrations achieved in the patients in
the current study, acts as a protector for cisplatin-associated hema-
tological side effects in both mice and cancer patients (38), pre-
sumably by modulation of accessory factors regulating hematopoi-
etic progenitor cells through the operation of cytokine cascades
(39). Further studied beyond the scope of this trial will be required
to fully elucidate the mechanisms underlying the platelet-sparing
effect of the paclitaxel–carboplatin combination.
The overall response rate of 54% observed in this Phase I
study is high also in view of the fact that almost half of the
patients had liver metastases. Because this regimen can be
administered over a short period of time, it is also attractive to
explore its activity as induction treatment or as part of a com-
bined modality treatment.
In conclusion, carboplatin targeted at AUC 4 in combina-
tion with 100 mg/m2 paclitaxel administered on days 1, 8, 15,
29, 36, and 43 is the recommended dose for untreated patients
with advanced esophageal cancer. Both the observed response
rate and toxicity profile compare favorable with other cisplatin-
Table 7 Summary of cremophor EL pharmacokinetic parameters
(n  13)a,b
Parameter Mean  SD Range
Cremophor EL dose, ml 16.4  1.04 14.8–18.0
Infusion duration, h 1.02  0.03 1.00–1.08
Cmax, l/mlc 2.67  0.33 2.06–3.15
AUC, l  h/ml 70.5  16.4 54.6–107
CL, ml/h/m2 123  23.0 78.1–153
Vss, liter/m2 4.49  0.54 3.71–5.56
T1/2,z, h 27.1  8.06 19.9–50.3
a All patients received paclitaxel as a 1-h infusion at a dose of 100
mg/m2, followed by carboplatin at a dose targeting an AUC of 4 mg 
min/ml (n  5) or AUC of 4.5 mg  min/ml (n  8). Data were
calculated using noncompartmental analysis.
b n, total number of patients studied.
c Cmax, peak plasma concentration; AUC, area under the plasma
concentration time curve extrapolated to infinity; CL, plasma clearance;
Vss, volume of distribution at steady state; T1/2,z, half-life of the terminal
disposition phase.
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based chemotherapy regimens used for patients with esophageal
cancer, and in addition to this, this regimen can be administered
in an outpatient setting, hereby improving patient convenience
for this specific group of patients. Currently, the recommended
schedule is further examined in a randomized Phase III study in
patients with advanced ovarian cancer.
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